Background The development of more potent selective oestrogen receptor antagonists and
degraders (SERDs) that can be orally administered could help to address the limitations of …

Abstract Purpose: The value of Ki67 measured on residual disease after neoadjuvant
chemotherapy is not sufficiently described. Experimental Design: Participants of the …

The main obstacle for designing effective treatment approaches in breast cancer is the
extensive and the characteristic heterogeneity of this tumor. The vast majority of critical …

We report that neurofibromin, a tumor suppressor and Ras-GAP (GTPase-activating protein),
is also an estrogen receptor-α (ER) transcriptional co-repressor through leucine/isoleucine …

Gene expression profiling has had a considerable impact on our understanding of breast
cancer biology. During the last decade, 4 intrinsic molecular subtypes of breast cancer …

Purpose: Addition of alpelisib to fulvestrant significantly extended progression-free survival
in PIK3CA-mutant, hormone receptor–positive (HR+) advanced/metastatic breast cancer in …

Importance Although neoadjuvant endocrine therapy (NET) is an alternative to
chemotherapy for strongly hormone receptor (HR)–positive and human epidermal growth …

Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study
compared the efficacy and safety of adjuvant letrozole versus anastrozole in …

Abstract Purpose The Recurrence Score test is validated to predict benefit of adjuvant
chemotherapy. TransNEOS, a translational study of New Primary Endocrine-therapy …

Importance The value of the intrinsic subtypes of breast cancer (luminal A, luminal B, human
epidermal growth factor receptor 2 [currently known as ERBB2, but referred to as HER2 in …